Novabay pharmaceuticals, inc. (NBY)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Sales:
Total sales, net

6,599

12,508

18,230

11,897

-

-

-

-

-

-

-

Product cost of goods sold

1,738

1,503

2,784

2,464

-

-

-

-

-

-

-

Product revenue, net

-

-

-

-

4,146

684

223

-

-

-

-

License, collaboration and distribution revenue

-

-

-

-

-

-

-

6,855

10,993

9,754

-

License and collaboration revenue

-

-

-

-

-

-

-

-

-

-

15,684

Other revenue

-

-

-

-

235

370

3,254

78

26

-

-

Total sales, net

-

-

-

-

4,381

1,054

3,477

-

-

-

-

Product revenue

-

-

-

-

-

-

-

14

-

-

-

Product cost of goods sold

-

-

-

-

1,261

486

162

8

-

-

-

Gross profit

4,861

11,005

15,446

9,433

3,120

568

3,315

6

-

-

-

Total other revenue

-

-

-

-

-

-

-

6,933

11,019

9,754

15,684

Operating expenses:
Research and development

184

259

410

1,371

5,728

9,483

12,461

9,275

9,911

8,616

7,337

Sales and marketing

8,767

12,789

13,711

11,809

10,523

1,754

-

-

-

-

-

General and administrative

5,310

5,828

8,636

7,235

8,006

6,235

-

-

5,429

5,654

5,607

Sales, general and administrative

-

-

-

-

-

-

6,340

5,973

-

-

-

Total operating expenses

14,261

18,876

22,757

20,415

24,257

17,472

18,801

15,248

15,340

14,270

12,944

Operating loss

-9,400

-7,871

-7,311

-10,982

-21,137

-16,904

-15,486

-8,309

-4,321

-4,516

2,740

Non-cash gain (loss) on changes in fair value of warrant liability

-749

-1,311

101

2,099

-2,149

-

-

-

-

-

-

Non-cash gain on changes in fair value of embedded derivative liability

424

-

-

-

-

-

-

-

-

-

-

Non cash loss on changes in fair value of warrant liability

-

-

-

-

-

1,664

-555

1,439

-732

-

-

Other expense, net

-1,425

19

12

-68

17

48

1

-155

-30

258

-36

Loss before provision for income taxes

-9,652

-6,541

-7,400

-13,149

-18,971

-

-

-

-

-

-

Loss before provision for income taxes

-

-

-

-

-

-15,192

-16,040

-7,025

-5,083

-4,258

2,704

Provision for income taxes

6

4

3

2

2

2

1

2

2

50

7

Net loss

-

-

-

-

-

-15,194

-16,042

-7,027

-5,085

-4,308

2,697

Change in Unrealized gains on available for sale securities

-

-

-

-

-

15

-2

31

-30

-14

-

Comprehensive loss

-

-

-

-

-

-15,179

-16,044

-6,996

-5,115

-4,322

-

Net loss and comprehensive loss

-9,658

-6,545

-7,403

-13,151

-18,973

-

-

-

-

-

-

Less: Preferred deemed dividend

800

-

-

-

-

-

-

-

-

-

-

Less: Retained earnings reduction related to warrants down round feature triggered

29

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-10,487

-6,545

-7,403

-

-

-

-

-

-

-

-

Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)

-

-

-

-

-6.82

-7.65

-10.51

-0.24

-0.20

-0.18

-

Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)

-0.48

-0.39

-0.48

-1.40

-

-

-

-

-

-

22,404.00

Net loss per share attributable to common stockholders (diluted) (in dollars per share)

-0.48

-0.46

-0.48

-1.40

-

-

-

-

-

-

23,115.00

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (in shares)

-

-

-

-

2,784

1,985

1,527

29,448

-

-

-

Weighted-average shares of common stock used in computing net loss per share attributable to common stockholders (basic and diluted) (in shares)

21,641

16,921

15,324

9,408

-

-

-

-

-

-

-

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (diluted) (in shares)

21,641

17,058

15,324

9,408

-

-

-

-

25,773

23,326

0

Product [Member]
Total sales, net

6,556

12,474

18,127

11,617

-

-

-

-

-

-

-

Product and Service, Other [Member]
Total sales, net

43

34

103

280

-

-

-

-

-

-

-